Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

PTC Therapeutics, Inc.

NASDAQ: PTCT · Life Sciences · 10 alerts · CIK 1070081

Share price
$60.97Close, Nov 16
Market cap
$5.09B
Shares outstanding
83.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PTC Therapeutics, Inc. filings on SEC EDGAR ↗

5:20 PM ET Form 4
Insider Selling

PTC Therapeutics Director Michael Schmertzler Sells $149K of Stock

Michael Schmertzler, Director, sold 2,500 shares of PTC Therapeutics, Inc. at $59.52 to $60.14 a share (average $59.61) in 2 transactions, worth $149K in total on Oct 14, 2026. Shares held after the trade: 1,291,594 (-0.0%).

Value
$149K
Shares
2,500
Average price
$59.61
Role
Director
Holding change
-0.0%
Trade date
Oct 14, 2026
5:20 PM ET Form 4
Insider Selling

PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding Sells $12.3K of Stock

Mark Elliott Boulding, Exec. VP and CLO, sold 192 shares of PTC Therapeutics, Inc. at $64.26 a share, worth $12.3K in total on Oct 9, 2026. Shares held after the trade: 105,272 (-0.2%).

Value
$12.3K
Shares
192
Price
$64.26
Role
Exec. VP and CLO
Holding change
-0.2%
Trade date
Oct 9, 2026
5:20 PM ET Form 4
Insider Selling

PTC Therapeutics Director Michael Schmertzler Sells $155K of Stock

Michael Schmertzler, Director, sold 2,447 shares of PTC Therapeutics, Inc. at $63.38 a share, worth $155K in total on Oct 7, 2026. Shares held after the trade: 1,294,147 (-0.2%).

Value
$155K
Shares
2,447
Price
$63.38
Role
Director
Holding change
-0.2%
Trade date
Oct 7, 2026
5:20 PM ET Form 4
Insider Selling

PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding Sells $133K of Stock

Mark Elliott Boulding, Exec. VP and CLO, sold 2,073 shares of PTC Therapeutics, Inc. at $64.03 to $64.16 a share (average $64.06) in 2 transactions, worth $133K in total between Oct 5, 2026 and Oct 6, 2026. Shares held after the trade: 105,272 (-0.4%).

Value
$133K
Shares
2,073
Average price
$64.06
Role
Exec. VP and CLO
Holding change
-0.4%
Trade date
Oct 5, 2026 to Oct 6, 2026
5:20 PM ET Form 4
Insider Selling

PTC Therapeutics Director Glenn Steele Jr. Md. Phd. Sells $782K of Stock

Glenn Steele Jr. Md. Phd., Director, sold 12,000 shares of PTC Therapeutics, Inc. at $65.16 a share, worth $782K in total on Sep 30, 2026. Shares held after the trade: 22,500 (-34.8%).

Value
$782K
Shares
12,000
Price
$65.16
Role
Director
Holding change
-34.8%
Trade date
Sep 30, 2026
5:20 PM ET Form 4
Insider Selling

PTC Therapeutics Director Michael Schmertzler Sells $1.35M of Stock

Michael Schmertzler, Director, sold 20,000 shares of PTC Therapeutics, Inc. at $66.58 to $68.45 a share (average $67.49) in 4 transactions, worth $1.35M in total between Sep 16, 2026 and Sep 17, 2026. Shares held after the trade: 1,296,594 (-0.0%).

Value
$1.35M
Shares
20,000
Average price
$67.49
Role
Director
Holding change
-0.0%
Trade date
Sep 16, 2026 to Sep 17, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.